Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database

Natalia Gonzalez Caldito, Afsaneh Shirani, Amber Salter, Olaf Stuve

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience